Manufacturer of Controlled Substances; Notice of Registration, 56614-56615 [E8-22877]
Download as PDF
<![CDATA[
56614
Federal Register / Vol. 73, No. 189 / Monday, September 29, 2008 / Notices
a bulk manufacturer of the basic classes
of controlled substances listed in
schedules I and II:
Drug
Schedule
mstockstill on PROD1PC66 with NOTICES
Methcathinone (1237) ..................................................................................................................................................................................
N-Ethylamphetamine (1475) ........................................................................................................................................................................
N,N-Dimethylamphetamine (1480) ...............................................................................................................................................................
4-Methylaminorex (cis isomer) (1590) .........................................................................................................................................................
Alpha-ethyltryptamine (7249) .......................................................................................................................................................................
Lysergic acid diethylamide (7315) ...............................................................................................................................................................
2,5-Dimethoxy-4-(n)-propylthiophenethylamine (7348) ................................................................................................................................
Tetrahydrocannabinols (7370) .....................................................................................................................................................................
Mescaline (7381) ..........................................................................................................................................................................................
4-Bromo-2,5-dimethoxyamphetamine (7391) ...............................................................................................................................................
4-Bromo-2,5-dimethoxyphenethylamine (7392) ...........................................................................................................................................
4-Methyl-2,5-dimethoxyamphetamine (7395) ...............................................................................................................................................
2,5-Dimethoxyamphetamine (7396) .............................................................................................................................................................
2,5-Dimethoxy-4-ethylamphetamine (7399) .................................................................................................................................................
3,4-Methylenedioxyamphetamine (7400) .....................................................................................................................................................
N-Hydroxy-3,4-methylenedioxyamphetamine (7402) ...................................................................................................................................
3,4-Methylenedioxy-N-ethylamphetamine (7404) ........................................................................................................................................
3,4-Methylenedioxymethamphetamine (MDMA) (7405) ..............................................................................................................................
4-Methoxyamphetamine (7411) ...................................................................................................................................................................
Alpha-methyltryptamine (7432) ....................................................................................................................................................................
Bufotenine (7433) .........................................................................................................................................................................................
Diethyltryptamine (7434) ..............................................................................................................................................................................
Dimethyltryptamine (7435) ...........................................................................................................................................................................
Psilocybin (7437) ..........................................................................................................................................................................................
Psilocyn (7438) .............................................................................................................................................................................................
5-Methoxy-N,N-diisopropyltryptamine (7439) ...............................................................................................................................................
N-Ethyl-1-phenylcyclohexylamine (7455) .....................................................................................................................................................
1-(1-Phenylcyclohexyl)pyrrolidine (7458) .....................................................................................................................................................
1-Phenylcyclohexylamine (7460) .................................................................................................................................................................
1-[1-(2-Thienyl)cyclohexyl]piperidine (7470) ................................................................................................................................................
Normorphine (9313) .....................................................................................................................................................................................
Methamphetamine (1105) ............................................................................................................................................................................
Phencyclidine (7471) ....................................................................................................................................................................................
Phenylacetone (8501) ..................................................................................................................................................................................
1-Piperidinocyclohexanecarbonitrile (8603) .................................................................................................................................................
Cocaine (9041) .............................................................................................................................................................................................
Codeine (9050) .............................................................................................................................................................................................
Dihydrocodeine (9120) .................................................................................................................................................................................
Dihydromorphine (9145) ...............................................................................................................................................................................
Ecgonine (9180) ...........................................................................................................................................................................................
Meperidine intermediate-B (9233) ................................................................................................................................................................
Noroxymorphone (9668) ..............................................................................................................................................................................
The company plans to manufacture
high purity drug standards used for
analytical applications only in clinical,
toxicological, and forensic laboratories.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Alltech Associates, Inc. to manufacture
the listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Alltech Associates Inc. to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
VerDate Aug<31>2005
16:59 Sep 26, 2008
Jkt 214001
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: September 22, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E8–22875 Filed 9–26–08; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated April 28, 2008 and
published in the Federal Register on
May 2, 2008 (73 FR 24313), Lin Zhi
International Inc., 687 North Pastoria
PO 00000
Frm 00074
Fmt 4703
Sfmt 4703
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
Avenue, Sunnyvale, California 94085,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed in
schedules I and II:
Drug
.......................................................
Tetrahydrocannabinols (7370) .....
3,4-Methylenedioxymethamphetamine (MDMA) (7405).
Cocaine (9041) .............................
Oxycodone (9143) ........................
Hydrocodone (9193) .....................
Methadone (9250) ........................
Dextropropoxyphene, bulk (nondosage forms) (9273).
Morphine (9300) ...........................
Schedule
I
I
II
II
II
II
II
II
The company plans to manufacture
the listed controlled substances as bulk
reagents for use in drug abuse testing.
E:\FR\FM\29SEN1.SGM
29SEN1
Federal Register / Vol. 73, No. 189 / Monday, September 29, 2008 / Notices
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of Lin
Zhi International Inc. to manufacture
the listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Lin Zhi International Inc. to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: September 22, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E8–22877 Filed 9–26–08; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
mstockstill on PROD1PC66 with NOTICES
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated May 15, 2008 and
published in the Federal Register on
May 27, 2008 (73 FR 30418), Siegfried
(USA), Inc., Industrial Park Road,
Pennsville, New Jersey 08070, made
application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
Oripavine (9330), a basic class of
controlled substance listed in schedule
II.
The company will use the above
listed controlled substance in the
manufacture of other controlled
substance intermediates for sale to its
customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Siegfried (USA), Inc. to manufacture the
listed basic class of controlled substance
is consistent with the public interest at
this time. DEA has investigated
Siegfried (USA), Inc. to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
VerDate Aug<31>2005
16:48 Sep 26, 2008
Jkt 214001
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic class of controlled substance
listed.
Dated: September 22, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E8–22879 Filed 9–26–08; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF LABOR
Occupational Safety and Health
Administration
[Docket No. OSHA–2008–0023]
Telecommunications; Extension of the
Office of Management and Budget’s
(OMB) Approval of Information
Collection (Paperwork) Requirements
Occupational Safety and Health
Administration (OSHA), Labor.
ACTION: Request for public comment.
AGENCY:
SUMMARY: OSHA solicits comments
concerning its proposal to extend OMB
approval of the information collection
requirement contained in the Standard
on Telecommunications (29 CFR
1910.268). The purpose of this
requirement is to ensure that employees
have been trained as required by the
Standard to prevent risk of death or
serious injury.
DATES: Comments must be submitted
(postmarked, sent, or received) by
November 28, 2008.
ADDRESSES: Electronically: You may
submit comments and attachments
electronically at https://
www.regulations.gov, which is the
Federal eRulemaking Portal. Follow the
instructions online for submitting
comments.
Facsimile: If your comments,
including attachments, are not longer
than 10 pages, you may fax them to the
OSHA Docket Office at (202) 693–1648.
Mail, hand delivery, express mail,
messenger, or courier service: When
using this method, you must submit
three copies of your comments and
attachments to the OSHA Docket Office,
Docket No. OSHA–2008–0023, U.S.
Department of Labor, Occupational
Safety and Health Administration,
Room N–2625, 200 Constitution
Avenue, NW., Washington, DC 20210.
Deliveries (hand, express mail,
PO 00000
Frm 00075
Fmt 4703
Sfmt 4703
56615
messenger, and courier service) are
accepted during the Department of
Labor’s and Docket Office’s normal
business hours, 8:15 a.m. to 4:45 p.m.,
e.t.
Instructions: All submissions must
include the Agency name and OSHA
docket number for the ICR (OSHA–
2008–0023). All comments, including
any personal information you provide,
are placed in the public docket without
change, and may be made available
online at https://www.regulations.gov.
For further information on submitting
comments see the ‘‘Public
Participation’’ heading in the section of
this notice titled ‘‘SUPPLEMENTARY
INFORMATION.’’
Docket: To read or download
comments or other material in the
docket, go to https://www.regulations.gov
or the OSHA Docket Office at the
address above. All documents in the
docket (including this Federal Register
notice) are listed in the https://
www.regulations.gov index; however,
some information (e.g., copyrighted
material) is not publicly available to
read or download through the Web site.
All submissions, including copyrighted
material, are available for inspection
and copying at the OSHA Docket Office.
You may also contact Theda Kenney at
the address below to obtain a copy of
the ICR.
FOR FURTHER INFORMATION CONTACT:
Theda Kenney or Todd Owen,
Directorate of Standards and Guidance,
OSHA, U.S. Department of Labor, Room
N–3609, 200 Constitution Avenue, NW.,
Washington, DC 20210; telephone (202)
693–2222.
SUPPLEMENTARY INFORMATION:
I. Background
The Department of Labor, as part of its
continuing effort to reduce paperwork
and respondent (i.e., employer) burden,
conducts a preclearance consultation
program to provide the public with an
opportunity to comment on proposed
and continuing information collection
requirements in accordance with the
Paperwork Reduction Act of 1995 (44
U.S.C. 3506(c)(2)(A)). This program
ensures that information is in the
desired format, reporting burden (time
and costs) is minimal, collection
instruments are clearly understood, and
OSHA’s estimate of the information
collection burden is accurate. The
Occupational Safety and Health Act of
1970 (the OSH Act) (29 U.S.C. 651 et
seq.) authorizes information collection
by employers as necessary or
appropriate for enforcement of the Act
or for developing information regarding
the causes and prevention of
E:\FR\FM\29SEN1.SGM
29SEN1
]]>Agencies
[Federal Register Volume 73, Number 189 (Monday, September 29, 2008)]
[Notices]
[Pages 56614-56615]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-22877]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration
By Notice dated April 28, 2008 and published in the Federal
Register on May 2, 2008 (73 FR 24313), Lin Zhi International Inc., 687
North Pastoria Avenue, Sunnyvale, California 94085, made application by
renewal to the Drug Enforcement Administration (DEA) to be registered
as a bulk manufacturer of the basic classes of controlled substances
listed in schedules I and II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
...........................
Tetrahydrocannabinols (7370)............... I
3,4-Methylenedioxymetham-phetamine (MDMA) I
(7405).
Cocaine (9041)............................. II
Oxycodone (9143)........................... II
Hydrocodone (9193)......................... II
Methadone (9250)........................... II
Dextropropoxyphene, bulk (non-dosage forms) II
(9273).
Morphine (9300)............................ II
------------------------------------------------------------------------
The company plans to manufacture the listed controlled substances
as bulk reagents for use in drug abuse testing.
[[Page 56615]]
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and determined that the registration of
Lin Zhi International Inc. to manufacture the listed basic classes of
controlled substances is consistent with the public interest at this
time. DEA has investigated Lin Zhi International Inc. to ensure that
the company's registration is consistent with the public interest. The
investigation has included inspection and testing of the company's
physical security systems, verification of the company's compliance
with state and local laws, and a review of the company's background and
history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with
21 CFR 1301.33, the above named company is granted registration as a
bulk manufacturer of the basic classes of controlled substances listed.
Dated: September 22, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E8-22877 Filed 9-26-08; 8:45 am]
BILLING CODE 4410-09-P
